Curanex Pharmaceuticals Inc
CURX
$4.02
$0.020.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 71.45% | 403.15% | 102,000.00% | 2,330.30% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 71.45% | 403.15% | 102,000.00% | 2,330.30% | |
| Operating Income | -71.45% | -403.15% | -102,000.00% | -2,330.30% | |
| Income Before Tax | -71.57% | -980.31% | -- | -2,330.30% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -71.57% | -980.31% | -- | -2,330.30% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -71.57% | -980.31% | -- | -2,330.30% | |
| EBIT | -71.45% | -403.15% | -102,000.00% | -2,330.30% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 95.74% | 72.99% | -- | -2,330.91% | |
| Normalized Basic EPS | 95.69% | 87.88% | -- | -2,355.88% | |
| EPS Diluted | 95.74% | 72.99% | -- | -2,330.91% | |
| Normalized Diluted EPS | 95.69% | 87.88% | -- | -2,355.88% | |
| Average Basic Shares Outstanding | 3,900.00% | 3,913.07% | 3,926.28% | 0.00% | |
| Average Diluted Shares Outstanding | 3,900.00% | 3,913.07% | 3,926.28% | 0.00% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |